Volume | 19,804 |
|
|||||
News | - | ||||||
Day High | 4.55 | Low High |
|||||
Day Low | 4.15 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Marker Therapeutics Inc | MRKR | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
4.33 | 4.15 | 4.55 | 4.30 | 4.335 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
280 | 19,804 | $ 4.35 | $ 86,179 | - | 0.6706 - 9.6799 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
16:43:09 | 30 | $ 4.47 | USD |
Marker Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
36.89M | 8.89M | - | 9.01M | -29.93M | -3.37 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Marker Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical MRKR Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 4.52 | 4.91 | 4.1101 | 4.53 | 22,668 | -0.22 | -4.87% |
1 Month | 3.68 | 4.91 | 3.40 | 4.22 | 21,253 | 0.62 | 16.85% |
3 Months | 5.29 | 5.41 | 3.40 | 4.35 | 20,122 | -0.99 | -18.71% |
6 Months | 4.70 | 6.1568 | 2.40 | 4.37 | 52,257 | -0.40 | -8.51% |
1 Year | 0.802 | 9.6799 | 0.6706 | 2.59 | 273,719 | 3.50 | 436.16% |
3 Years | 23.40 | 36.50 | 0.6706 | 11.39 | 612,843 | -19.10 | -81.62% |
5 Years | 67.50 | 91.70 | 0.6706 | 20.18 | 665,874 | -63.20 | -93.63% |
Marker Therapeutics Description
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart. |